Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer.

APAF1 hypoxia miR-23a-3p miRNA ovarian cancer platinum response prognostic marker

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
04 Jul 2021
Historique:
received: 15 04 2021
accepted: 25 06 2021
entrez: 20 7 2021
pubmed: 21 7 2021
medline: 21 7 2021
Statut: epublish

Résumé

The onset of chemo-resistant recurrence represents the principal cause of high-grade serous ovarian carcinoma (HGSOC) death. HGSOC masses are characterized by a hypoxic microenvironment, which contributes to the development of this chemo-resistant phenotype. Hypoxia regulated-miRNAs (HRMs) represent a molecular response of cancer cells to hypoxia and are involved in tumor progression. We investigated the expression of HRMs using miRNA expression data from a total of 273 advanced-stage HGSOC samples. The miRNAs associated with chemoresistance and survival were validated by RT-qPCR and target prediction, and comparative pathway analysis was conducted for target gene identification. Analysis of miRNA expression profiles indicated miR-23a-3p and miR-181c-5p over-expression as associated with chemoresistance and poor PFS. RT-qPCR data confirmed upregulation of miR-23a-3p in tumors from chemoresistant HGSOC patients and its significant association with shorter PFS. In silico miR-23a-3p target prediction and comparative pathway analysis identified platinum drug resistance as the pathway with the highest number of miR-23a-3p target genes. Among them, APAF-1 emerged as the most promising, being downregulated in platinum-resistant patients and in HGSOC chemo-resistant cells. These results highlight miR-23a-3p as a potential biomarker for HGSOC platinum response and prognosis and the miR23a-3p/APAF1 axis as a possible target to overcome platinum-resistance.

Identifiants

pubmed: 34283087
pii: cancers13133358
doi: 10.3390/cancers13133358
pmc: PMC8268862
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Fondazione Cariplo
ID : 2013-0815
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG 21837

Références

Semin Oncol. 2006 Apr;33(2 Suppl 6):S12-6
pubmed: 16716798
PLoS One. 2018 Nov 26;13(11):e0207319
pubmed: 30475821
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
PLoS One. 2013;8(2):e56647
pubmed: 23437196
Mol Cell Biol. 2007 Mar;27(5):1859-67
pubmed: 17194750
Oncotarget. 2015 May 10;6(13):11342-56
pubmed: 25839163
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
Oncotarget. 2016 Mar 22;7(12):13464-78
pubmed: 26859576
BMC Bioinformatics. 2012 Jan 31;13:20
pubmed: 22292714
Clin Transl Oncol. 2009 Sep;11(9):564-71
pubmed: 19775995
J Clin Oncol. 2012 Jun 10;30(17):2039-45
pubmed: 22529265
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5331-6
pubmed: 24706848
BMC Cancer. 2017 May 25;17(1):366
pubmed: 28545541
Cancers (Basel). 2018 Dec 20;11(1):
pubmed: 30577536
J Cell Mol Med. 2016 Dec;20(12):2341-2348
pubmed: 27419385
Oncogenesis. 2016 Jan 25;5:e190
pubmed: 26807645
Clin Chem. 2015 Nov;61(11):1333-42
pubmed: 26408530
Cancer Biol Ther. 2019;20(6):897-911
pubmed: 30862230
Nucleic Acids Res. 2018 Jan 4;46(D1):D239-D245
pubmed: 29156006
Cancer Metastasis Rev. 2015 Mar;34(1):19-40
pubmed: 25544368
Nucleic Acids Res. 2012 Jan;40(2):761-74
pubmed: 21917858
J Pharmacokinet Biopharm. 1984 Feb;12(1):83-91
pubmed: 6747820
Cancer Res. 2011 Jul 1;71(13):4720-31
pubmed: 21555366
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Commun. 2016 Mar 29;7:11150
pubmed: 27021436
Nat Rev Cancer. 2012 Oct;12(10):699-709
pubmed: 23001349
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Oncogene. 2016 Aug 18;35(33):4312-20
pubmed: 26725326
Br J Cancer. 2016 Sep 6;115(6):731-40
pubmed: 27537390
Oncol Lett. 2018 Jul;16(1):262-266
pubmed: 29928410
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Int J Cancer. 2013 Aug 15;133(4):867-78
pubmed: 23389731
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
J Cell Mol Med. 2011 Jul;15(7):1593-602
pubmed: 20716115
Int J Clin Exp Med. 2015 Aug 15;8(8):13329-34
pubmed: 26550261
Cancer Lett. 2017 Mar 1;388:320-327
pubmed: 28017893
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W169-73
pubmed: 23680784
Int J Mol Sci. 2014 Jul 02;15(7):11713-29
pubmed: 24992592
J Clin Oncol. 2019 Sep 10;37(26):2317-2328
pubmed: 31216226
Cancer Biol Ther. 2008 Feb;7(2):255-64
pubmed: 18059191
Int J Cancer. 2020 Jul 15;147(2):565-574
pubmed: 32096871
Biochem Biophys Res Commun. 2018 Mar 4;497(2):513-520
pubmed: 29452092
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W186-92
pubmed: 17526521
Elife. 2015 Aug 12;4:
pubmed: 26267216

Auteurs

Paola Todeschini (P)

Angelo Nocivelli' Institute of Molecular Medicine, ASST Spedali Civili di Brescia, University of Brescia, 25121 Brescia, Italy.
Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.

Elisa Salviato (E)

Department of Biology, University of Padua, 35122 Padua, Italy.

Chiara Romani (C)

Angelo Nocivelli' Institute of Molecular Medicine, ASST Spedali Civili di Brescia, University of Brescia, 25121 Brescia, Italy.

Vittoria Raimondi (V)

Istituto Oncologico Veneto IOV-IRCCS, 35128 Padua, Italy.

Francesco Ciccarese (F)

Istituto Oncologico Veneto IOV-IRCCS, 35128 Padua, Italy.

Federico Ferrari (F)

Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
Department of Clinical and Experimental Sciences, Division of Obstetrics and Gynecology, University of Brescia, 35122 Brescia, Italy.

Germana Tognon (G)

Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.

Sergio Marchini (S)

Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, 20156 Milan, Italy.

Maurizio D'Incalci (M)

Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, IRCCS, 20156 Milan, Italy.

Laura Zanotti (L)

Angelo Nocivelli' Institute of Molecular Medicine, ASST Spedali Civili di Brescia, University of Brescia, 25121 Brescia, Italy.
Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.

Antonella Ravaggi (A)

Angelo Nocivelli' Institute of Molecular Medicine, ASST Spedali Civili di Brescia, University of Brescia, 25121 Brescia, Italy.
Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
Department of Clinical and Experimental Sciences, Division of Obstetrics and Gynecology, University of Brescia, 35122 Brescia, Italy.

Franco Odicino (F)

Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
Department of Clinical and Experimental Sciences, Division of Obstetrics and Gynecology, University of Brescia, 35122 Brescia, Italy.

Enrico Sartori (E)

Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
Department of Clinical and Experimental Sciences, Division of Obstetrics and Gynecology, University of Brescia, 35122 Brescia, Italy.

Donna M D'Agostino (DM)

Istituto Oncologico Veneto IOV-IRCCS, 35128 Padua, Italy.
Department of Biomedical Sciences, University of Padua, 35131 Padua, Italy.

Michele Samaja (M)

Department of Health Science, University of Milan, 20122 Milan, Italy.

Chiara Romualdi (C)

Department of Biology, University of Padua, 35122 Padua, Italy.

Eliana Bignotti (E)

Angelo Nocivelli' Institute of Molecular Medicine, ASST Spedali Civili di Brescia, University of Brescia, 25121 Brescia, Italy.
Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.

Classifications MeSH